JOHOR BAHRU, Nov 23 (Bernama) -- The Rapid Transit System (RTS) official launch on 22 Nov 2020 coupled with Budget 2021 allocation means all-systems-go and 8 freehold properties within 15-minute walking distance to the RTS hub will be in high demand.
Jerren Lai, Head of Research at Datamine Malaysia said, "The Iskandar Property Census 2020 Q3 Report singles out 8 freehold properties walking distance to the RTS hub that will have an added premium as Woodlands is earmarked as the third Regional Centre and largest Northern economic hub of Singapore.” Singapore Woodlands is a thriving commercial and industrial node where its Small and Medium Enterprises (SMEs) currently employ a large pool of Malaysians whose expected salary is lower as they live across the Causeway and the pool will get much larger once RTS completes. Strong demand will also come from Singapore HDB leasehold dwellers who are experiencing the lease-decay problem. About 80 percent of Singaporeans live in HDB flats and 100,000 of these units are nearing 60 years where banks are reluctant to offer loans to new purchasers. Iskandar freehold properties will be an affordable escape route for them. The 8 properties are Tri Tower and Suasana, 4-minute and 7-minute walk respectively to the hub and priced around RM1,300psf. R&F Princess Cove with fully covered walkway is a 9-minute walk priced at RM910psf. Sky Habitat 10-minute walk at RM800psf, Skysuites and V Summerplace 12-minute walk at RM635psf and RM748psf respectively while Paragon Suites 15-minute walk at RM880psf. Upcoming Twin Tower 5-minute walk at RM791psf. Comparing Singapore Woodlands vs JB CIQ property price, the Urban Redevelopment Authority of Singapore (URA) records Woodland’s median price at SGD799psf (RM2,397psf) while Iskandar Property Census 2020 Q3 reported JB CIQ prices at RM921psf. Lai said, "Private property price between the two nodes exceeds 320 percent differential but will likely narrow to around 30 percent upon RTS completion. JB CIQ prices will gradually appreciate in tandem with RTS progress from RM921psf now to around RM1,700psf.” Danga Bay, a prime sea-frontal area where China Country Garden made its debut and Tropez - the first modern condominium in JB, will likely hit RM1,200psf or half of Woodlands’ median price. The RTS journey is projected to take less than 10 minutes to connect the two regions and the state-of-art immigration clearance system that mirrors Shenzhen-HK crossing is said to be on the cards. Malaysian real estate valuers will need a paradigm shift in the way they value Iskandar properties as the Singapore factor will drive prices benchmarked against Woodlands rather than historical local transaction prices. Datamine Datamine Malaysia is a market research firm that pioneered the Iskandar Property Census research. The 6-monthly tracking survey has been on-going since 2012 and uses census instead of sampling data to give prices, supply and demand, hotspot and forecast outlook. Photo link: https://1drv.ms/u/s!Ai3HzmW_0gEFgf4AYuxJrdOtuJAIsA?e=tnzij9 SOURCE: Datamine http://mrem.bernama.com/viewsm.php?idm=38754
0 Comments
PALO ALTO, Calif., Nov 25 (Bernama-BUSINESS WIRE) -- Bitcoin Latinum, the next-generation Bitcoin fork capable of massive transaction volume, digital asset management, cyber security, and capacity is announcing its official pre-sale launch. Bitcoin Latinum will trade under the symbol LTNM with a total supply of 888,888,888 LTNM [verifiable by LTNM]. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005585/en/ Bitcoin Latinum is now available for pre-sale on bitcoinlatinum.com and will be available on exchanges in 2021. Bitcoin Latinum is an enhanced Bitcoin fork. The Bitcoin Latinum algorithm and infrastructure break barriers and speed limits that have prevented some virtual currencies from achieving practical, real-time use. Bitcoin Latinum taps into the new wave of crypto DeFi — decentralized finance — for its role in independent digital transactions. According to Nasdaq, the total DeFi related cryptocurrency market recently passed $14 billion, up from $1 billion in February 2020. mrem.bernama.com/viewsm.php?idm=38784 HUMANIGEN AUSTRALIA PROPRIETARY LIMITED ESTABLISHED TO FACILITATE ASIA-PACIFIC GROWTH PLANS25/11/2020 · New Humanigen entity in Australia creates focused opportunity for partnering, regional clinical trials and market access
· Structure allows for attractive financial incentives supported by the Australian government BURLINGAME, Calif., Nov 24 (Bernama-BUSINESS WIRE) -- Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced the establishment of Humanigen Australia Proprietary Limited (“Humanigen Australia Pty Ltd”), through which Humanigen intends to assess potential partnering opportunities, facilitate clinical development programs, and conduct other corporate and business development activities in the Asia-Pacific region. The first of these was announced on November 3, with the execution of a licensing agreement for lenzilumab for South Korea and the Philippines. The clinical trials that are ongoing, or in advanced planning in Australia are: Lenzilumab in cancer patients who are COVID-19 positive and have pneumonia as part of the C-SMART (COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomized Trial) The C-SMART study is led by the National Centre for Infections in Cancer at Peter MacCallum Cancer Centre and will be conducted at five Australian sites in Melbourne and Sydney. This study will include over 1,000 cancer patients at risk of, or known positive for, COVID-19 infection, with a subset of patients in the lenzilumab arm. The study is supported by a grant from the Australian Government's Medical Research Future Fund. Lenzilumab in refractory chronic myelomonocytic leukemia (CMML) as part of the PREcision Approach to CHronic Myelomonocytic Leukaemia (PREACH-M) trial Humanigen is in advanced planning for a Phase 2 study of lenzilumab in combination with azacitidine in newly-diagnosed CMML patients who express NRAS/KRAS/CBL mutations, which are known to be hypersensitive to granulocyte macrophage-colony stimulating factor (GM-CSF) and therefore may lend themselves to responsiveness to lenzilumab treatment. CMML is a rare form of hematologic cancer with no FDA-approved treatment options and a three-year overall survival rate of 20% and median overall survival of 20 months.¹,² The study is funded by grant from the Australian Government's Medical Research Future Fund and is expected to commence in 2021. Ifabotuzumab in glioblastoma multiforme (GBM) This Phase 1 trial has enrolled 11 of the 12 patients targeted for full enrollment. Results are expected to be available in the first half of 2021. Professor Andrew Scott, Head, Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, and Professor, School of Cancer Medicine, La Trobe University, who has been instrumental in the research and development of both lenzilumab and ifabotuzumab, said, "The establishment of Humanigen Australia Pty Ltd speaks to the importance and culmination of 20 years of research for these two novel antibodies, which we helped discover and develop in Australia. We hope that lenzilumab will have a major impact in the treatment of COVID-19 patients. Ifabotuzumab holds promise as a novel approach to target the tumour microenvironment in a range of solid tumors." Bob Atwill, Head of Asia-Pacific Region at Humanigen said, “Humanigen’s expansion strategy in COVID-19 includes conducting regional clinical trials, local manufacturing, partnering and potential early market entry. Some of these opportunities may allow Humanigen Australia Pty Ltd to benefit from certain financial and tax incentives offered by the Australian government, including a potential 43.5% rebate on eligible research and development expenditures. This is a critical moment for important advancements in biotechnology and healthcare, and I look forward to progressing lenzilumab and the rest of the Company’s pipeline in the Asia-Pacific region as we grow Humanigen Australia Pty Ltd.” About Humanigen, Inc. Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company’s immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com. Forward-Looking Statements This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations surrounding our operational, research, development or commercialization activities in the Asia Pacific region, and our ability to mitigate the impact of COVID-19, to develop CAR-T or solid cancer therapies or to prevent or treat GvHD via any of the technologies in our current pipeline. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to conduct the Phase III study and grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law. 1. Patnaik MM, Tefferi A. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol. Jan 2020;95(1):97-115. doi:10.1002/ajh.25684 2. Coston T, Pophali P, Vallapureddy R, et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol. Jul 2019;94(7):767-779. doi:10.1002/ajh.25488 View source version on businesswire.com: https://www.businesswire.com/news/home/20201123006238/en/ Contact Media Cammy Duong Westwicke, an ICR company [email protected] 203-682-8380 Investors Alan Lada Solebury Trout [email protected] 617-221-8006 Source : Humanigen, Inc. --BERNAMA Zynga and Automotive Tuner Liberty Walk Launch One-Of-A-Kind Design Competition for CSR Racing 2’s New Elite Tuners Feature (Photo: Business Wire) The Winning Design of CSR2’s Elite Tuners: ‘Design A Wrap’ Competition Will be Featured in Game and Placed on a Real-World Car Designed by Liberty Walk SAN FRANCISCO, Nov 25 (Bernama-BUSINESS WIRE) -- Today, Zynga (Nasdaq:ZNGA), a global leader in interactive entertainment, announced a partnership with Japanese premier car tuner Liberty Walk for the launch of the new Elite Tuners feature and ‘Design A Wrap’ competition in CSR Racing 2 (CSR2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005059/en/ Starting December 9, players can enter the exclusive mobile racing competition by designing a custom car-wrap to be featured in CSR2 and the contest winner will have their design placed onto a real-world Toyota Supra by Liberty Walk. To enter, players will upload their player-designed wraps to social media, tagging @CSRRacing and using the hashtag #CSR2Wrap. Players will be encouraged to like and share their favorite designs. The top 10 designs selected will be presented to the Liberty Walk team, who will then choose the final winner on February 20, 2021 through a special unveiling of the selected car design. In announcing the partnership, Liberty Walk’s founder Wataru San, along with his team, released a video teasing the new Elite Tuner feature in CSR2. Elite Tuners is one of the largest customization expansions in CSR2’s history, giving players unprecedented freedom to express their identity with deeper customization such as body kits, spoilers and more. Players can also elevate their performance and add rare cars to their existing collection. “We’re excited to partner with the iconic Liberty Walk team to deliver the Elite Tuners feature in CSR2 as a best-in-class customization experience for our players across the globe,” said Julian Widdows, Vice President of CSR2. “To have Liberty Walk bring to life a custom car-wrap design is a dream come true for any player. I cannot wait to see the creativity and designs coming from our players.” “We have collaborated with CSR Racing 2 for quite a few years now,’” said Liberty Walk’s founder Wataru San. “They recreated our body kits the best and respected our design and style. We trust them and it makes me very happy to appear in the game during my own event. We have been doing our best to please ours and CSR2's fans.” CSR2 is available to download for free on the App Store as well as on Google Play. For more information about CSR2, visit the game’s community channels on Facebook, Instagram, Twitter and YouTube. To view the supporting assets for CSR2, please click here: https://www.dropbox.com/sh/iw2xzdy94t2sgw6/AAAgs6JF_NJBY_cVhYTum_z7a?dl=0 ABOUT ZYNGA INC. Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR Racing™, Empires & Puzzles™, Merge Dragons!™, Merge Magic!™, Toon Blast™, Toy Blast™ and Words With Friends™. Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, the U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter, Instagram, Facebook or the Zynga blog. FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements, relating to, among other things, the release of future CSR Racing 2 game features and events. Forward-looking statements often include words such as "outlook," "projected," “planned,” "intends," "will," "anticipate," "believe," "target," "expect," and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties, and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties, and assumptions are or will be described in greater detail in our public filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained by visiting our Investor Relations website at http://investor.zynga.com or the SEC’s web site at www.sec.gov. View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005059/en/ Contact ZYNGA MEDIA CONTACT Kenny Johnston [email protected] | (602) 999-1890 Source : Zynga KUALA LUMPUR, Nov 20 -- QED Investors, a leading boutique venture capital firm has entered the Indian and Southeast Asian market, hiring Sandeep Patil to lead its investments within the region.
With the addition of Patil, QED will expand its global footprint, adding India and Southeast Asia to existing work in North America, South America and the United Kingdom. Founded in 2007, QED Investors has invested in more than 120 companies, including 13 unicorns, and has over US$1.8 billion under management. (US$1 = RM4.089) Notable investments include Nubank, SoFi, Credit Karma, Klarna, GreenSky, Avant, Flywire, Remitly, QuintoAndar, Creditas, ClearScore and Konfio, according to a statement. “QED has evaluated entering the Asian continent closely and we are excited to welcome Sandeep to help us invest in the best fintech companies the market has to offer,” said QED Investors Co-Founder and Managing Partner, Nigel Morris. QED is known for its singular focus on fintech and its more than 200 years of operator experience. Patil added significant depth in both areas and helped launch consumer and SME lending business at Flipkart and contributed to its fundraise and eventual sale to Walmart. He was the Managing Director and Chief Executive Officer for India at Truecaller where he directed Adtech, Payments, FinTech, SME/Enterprise and Developer businesses, which doubled the company’s revenues and achieved net income profitability despite the pandemic. Additionally, with Patil, QED has recruited Camila Key Saruhashi as a Principal based in San Francisco and Adams Conrad as a Principal in New York. -- BERNAMA |
Archives
April 2023
|